Masimo (MASI)
(Delayed Data from NSDQ)
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
Medtronic Launches Grafton DBM Bone Grafting Product in Japan
by Zacks Equity Research
Grafton DBM to strengthen Medtronic's (MDT) foothold in Japan.
Medtronic Gets FDA Approval for Accurian RF Ablation Platform
by Zacks Equity Research
Medtronic's (MDT) RF ablation platform will use radio waves to provide relief from chronic pain.
Integra Rides on Channel Expansion Strategy, New Alliances
by Zacks Equity Research
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
ResMed Inks Deal With PharMerica on Medication Management
by Zacks Equity Research
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
DexCom (DXCM) Gets Health Canada Approval for G6 CGM System
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.
Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
by Zacks Equity Research
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
by Zacks Equity Research
Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
by Zacks Equity Research
Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.
Here's What Will Give Shape to Medtronic's (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.
Can Canadian Market Drive Canopy Growth (CGC) Q3 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is expected to benefit from solid top-line contribution from the Canadian medical cannabis market and the legalization of the recreational use of cannabis in Q3.
Can Global Industrial Unit Aid Ecolab's (ECL) Q4 Earnings?
by Zacks Equity Research
Ecolab's (ECL) preliminary Q4 earnings are likely to fall short of estimates.
3 Medical Instruments Stocks Likely to Beat Estimates in Q4
by Zacks Equity Research
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
Why Masimo (MASI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stock Market News For Jan 10, 2019
by Zacks Equity Research
Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.
Masimo's (MASI) Preliminary Results for 2018 Cheer Investors
by Zacks Equity Research
Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Masimo (MASI) Down 3.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.